Jonathan Schoenfeld, MD, MPH, discusses the immunologic effects of chemotherapy plus radiation, as well as radiation alone.
Jonathan Schoenfeld, MD, MPH, attending radiation oncologist, assistant professor, Harvard Medical School, Dana Farber Cancer Institute/Brigham and Women's Hospital, discusses the immunologic effects of chemotherapy plus radiation, as well as radiation alone.
Schoenfeld says he and his team looked at chemokines, part of the cytokines family, and their mediation abilities outside the treatment field, as well as circulating T cells. He adds that some T cells investigated included CD8-positive T cells, CD4-positive T cells, as well as markers of active T cells and T regulatory cells.
Schoenfeld says chemotherapy and radiation have long been used for their immune suppressive effects, though chemotherapy and radiation given in a certain way can cause immunologic cell death. This ability could synergize with immunotherapy and immune checkpoint blockade treatments currently being developed.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More